Document text
Principal Investigator: Taia Wang
Organization: STANFORD UNIVERSITY
Fiscal Year: 2020
Award: $931,365
Funding agency: National Cancer Institute
PROJECT 1: SUMMARY
As established through decades of research in protective immunity against infectious pathogens, achieving
durable immunity against SARS-CoV-2 will require specific functional properties of antibodies, B cells and T cells
that need to be defined through detailed repertoire studies. Antibody responses to viral infections in humans are
varied and of widely divergent clinical significance. Pre-existing, reactive antibodies or antibodies that are formed
early during infection can engage virus particles, forming immune complexes that may neutralize or mediate
clearance of the virus. On the other hand, immune complexes can also promote inflammation and exacerbate
symptoms of disease. SARS-CoV-2 infections can be asymptomatic or cause disease, COVID-19, which
manifests with a spectrum of symptoms ranging from mild to life threatening pneumonia and cytokine
dysregulation. The role of antibodies in protection against SARS-CoV-2 infections and whether antibodies may
play a role in promoting symptoms of COVID-19 remains unknown. In Project 1, we will define the heterogeneity
of antibody responses produced during SARS-CoV-2 infections and test the hypothesis that particular antibody
responses, with respect to the target antigen(s), specific epitopes and antibody effector functions, are required
for protection against SARS-CoV-2 infections. We will perform studies under the following specific aims: Aim 1:
Characterize antibodies elicited by SARS-CoV-2; Aim 2: Define antibody correlates of COVID-19 pathogenesis
and protection. These studies will include structure determination by cryo-electron microscopy that will delineate
the main binding epitopes and molecular characteristics of antibody recognition against the SARS-CoV-2 spike
protein. Further, we will investigate whether there are antibody profiles that correlate with more severe outcomes
in COVID-19. Results from these studies will guide the development of safe and effective vaccines and
monoclonal antibodies for the prevention and treatment of COVID-19.
Terms: <2019 novel coronavirus><2019-nCoV><Alanine><Amino Acids><Antibodies><Antibody Response><Antibody Specificity><Antibody-Secreting Cells><Antigen Targeting><Antigen-Antibody Complex><Antigenic Determinants><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Binding Determinants><COVID-19><COVID19><Cell Line><CellLine><Characteristics><Clinical><Clinical Treatment Moab><Clonal Expansion><Collaborations><Cryo-electron Microscopy><Cryoelectron Microscopy><Demographic Factors><Development><Disease><Disorder><Dissection><Electron Cryomicroscopy><Engineering><Epitope Mapping><Epitopes><Escape Mutant><Evaluation><Genetic><Health><Heterogeneity><Human><Humoral Immunities><IgG Receptors><Immune Complex><Immunity><Immunoglobulin G Receptor><Immunoglobulin-Secreting Cells><Infection><Inflammation><Investigators><Joints><Kinetics><Life><MAb Therapeutics><Maps><Mediating><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Memory><Memory B Cell><Memory B-Lymphocyte><Methods><Modern Man><Molecular><Molecular Interaction><Monoclonal Antibodies><Mucosa><Mucosal Tissue><Mucous Membrane><Mutate><Outcome><Pathogenesis><Patients><Phenotype><Play><Pneumonia><Population><Prevention><Property><Proteins><RNA Viruses><Research><Research Personnel><Researchers><Resolution><Role><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Sampling Studies><Serologic><Serologic tests><Serological><Serological Tests><Severe acute respiratory syndrome coronavirus 2><Sorting - Cell Movement><Specificity><Strains Cell Lines><Structure><Surface Proteins><Symptoms><T-Cells><T-Lymphocyte><Testing><Therapeutic Monoclonal Antibodies><Therapeutic antibodies><Vaccine Adjuvant><Vaccine Design><Vaccines><Viral Antigens><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virion><Virus><Virus Diseases><Virus Particle><Work><Wuhan coronavirus><aminoacid><antibody-based immunity><clinical significance><clinically significant><corona virus disease 2019><coronavirus disease 2019><cryo-EM><cryoEM><cultured cell line><cytokine><design><designing><developmental><gamma Fc Receptors><mAbs><monoclonal antibody drugs><mutant><new vaccines><next generation vaccines><novel vaccines><pandemic><pandemic disease><passive antibodies><pathogen><reconstitute><reconstitution><response><serology><seropositive><social role><sorting><therapeutic mAbs><thymus derived lymphocyte><tool><trend><vaccine efficacy><viral infection><virus antigen><virus infection><virus protein><virus-induced disease>